WA
ALNY icon

Waverly Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Waverly Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Sell
823
-84
-9% -$25.3K ﹤0.01% 1520
2026
Q1 		$300K Buy
907
+67
+8% +$22.8K ﹤0.01% 1299
2025
Q4 		$334K Sell
840
-25
-3% -$11.1K ﹤0.01% 1165
2025
Q3 		$394K Buy
+865
New +$352K ﹤0.01% 940

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Waverly Advisors's ALNY Position: Q2 2026 in Review

Waverly Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 9.3% in Q2 2026, selling an estimated $25.3K and leaving 823 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #1520.

Waverly Advisors first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $394K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Waverly Advisors held 823 shares of Alnylam Pharmaceuticals worth $248K as of Q2 2026.
  • Waverly Advisors sold 84 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $25.3K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Waverly Advisors's portfolio in Q2 2026, its #1520 holding.
  • Waverly Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Waverly Advisors's Alnylam Pharmaceuticals position peaked at $394K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.